Now showing items 1-6 of 6
Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT
BACKGROUND: Very late-onset (aged & greater than 60 years) schizophrenia-like psychosis (VLOSLP) occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy or risks of antipsychotic treatment. ...
Relative toxicity of mood stabilisers and antipsychotics: case fatality and fatal toxicity associated with self-poisoning
Background: Bipolar and other psychiatric disorders are associated with considerably increased risk of suicidal behaviour, which may include self-poisoning with medication used to treat the disorder. Therefore, choice of ...
Effect of agomelatine 25-50mg on functional outcomes in patients with major depressive disorder
Purpose: The purpose of this work is to investigate the effect of agomelatine on functioning compared with placebo in patients suffering from Major Depressive Disorder (MDD). Methods: Data from two randomized, parallel, ...
Lamotrigine for people with borderline personality disorder: A Randomised Control Trial
Background: No drug treatments are currently licensed for the treatment of borderline personality disorder (BPD). Despite this, people with this condition are frequently prescribed psychotropic medications and often with ...
The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: A randomized placebo-controlled trial
Objective: The authors examined whether lamotrigine is a clinically effective and cost-effective treatment for people with borderline personality disorder. Method: This was a multicenter, double-blind, placebo-controlled ...
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial
Background: Very late (aged & greater than 60 years) onset schizophrenia-like psychosis occurs frequently but no placebo-controlled, randomised trials have assessed the efficacy and risks of antipsychotic treatment. We ...